DexCom, Inc is a diagnostics & research business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. DexCom employs 5,500 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in DexCom
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DXCM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- DXCM shares summary
- Compare share dealing platforms
- Is DXCM stock a buy or sell?
- Stock performance over time
- Can I short DXCM shares?
- Is DXCM suitable for ethical investing?
- Are DXCM shares over-valued?
- DexCom's financials
- How volatile are DXCM shares?
- Does DexCom pay a dividend?
- Other common questions
DexCom stock price (NASDAQ: DXCM)Use our graph to track the performance of DXCM stocks over time.
DexCom shares at a glance
|Latest market close||$382.91|
|52-week range||$305.63 - $456.23|
|50-day moving average||$422.94|
|200-day moving average||$386.16|
|Wall St. target price||$477.95|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.21|
Buy DexCom shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy DexCom stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
DexCom price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-10.33%|
|3 months (2021-04-30)||-0.83%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Is DexCom under- or over-valued?
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's P/E ratio
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 87x. In other words, DexCom shares trade at around 87x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's PEG ratio
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 19.6752. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $374.4 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2 billion|
|Operating margin TTM||15.39%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||5.7%|
|Return on equity TTM||36.23%|
|Market capitalisation||$43.6 billion|
TTM: trailing 12 months
Shorting DexCom shares
There are currently 4.1 million DexCom shares held short by investors – that's known as DexCom's "short interest". This figure is 6.9% up from 3.8 million last month.
There are a few different ways that this level of interest in shorting DexCom shares can be evaluated.
DexCom's "short interest ratio" (SIR)
DexCom's "short interest ratio" (SIR) is the quantity of DexCom shares currently shorted divided by the average quantity of DexCom shares traded daily (recently around 856341.71907757). DexCom's SIR currently stands at 4.77. In other words for every 100,000 DexCom shares traded daily on the market, roughly 4770 shares are currently held short.
However DexCom's short interest can also be evaluated against the total number of DexCom shares, or, against the total number of tradable DexCom shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DexCom's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DexCom shares in existence, roughly 40 shares are currently held short) or 0.0425% of the tradable shares (for every 100,000 tradable DexCom shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DexCom.
Find out more about how you can short DexCom stock.
DexCom's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
DexCom's total ESG risk score
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
DexCom's environmental score
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
DexCom's social score
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
DexCom's governance score
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
DexCom's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.18|
|Total ESG percentile||50.12|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
DexCom share dividends
We're not expecting DexCom to pay a dividend over the next 12 months.
DexCom share price volatility
Over the last 12 months, DexCom's shares have ranged in value from as little as $305.63 up to $456.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 0.7824. This would suggest that DexCom's shares are less volatile than average (for this exchange).
DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators.
Stocks similar to DexCom
DexCom in the news
Dexcom Reports Second Quarter 2021 Financial Results
DexCom, Inc. 2021 Q2 - Results - Earnings Call Presentation
Stocks That Hit 52-Week Highs On Thursday
Frequently asked questionsWhat percentage of DexCom is owned by insiders or institutions?
Currently 0.526% of DexCom shares are held by insiders and 97.514% by institutions. How many people work for DexCom?
Latest data suggests 5,500 work at DexCom. When does the fiscal year end for DexCom?
DexCom's fiscal year ends in December. Where is DexCom based?
DexCom's address is: 6340 Sequence Drive, San Diego, CA, United States, 92121 What is DexCom's ISIN number?
DexCom's international securities identification number is: US2521311074 What is DexCom's CUSIP number?
DexCom's Committee on Uniform Securities Identification Procedures number is: 252131107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert